New pill shows promise for Hard-to-Treat blood cancer
NCT ID NCT05141682
First seen Jun 25, 2026 · Last updated Jul 29, 2026 · Updated 5 times
Summary
This early-phase trial is testing an oral chemotherapy drug called azacitidine (CC-486) in 11 adults with a rare type of leukemia (T-LGLL) that has come back or not responded to prior treatment. The study aims to find the best dose and see how well the drug works at shrinking or controlling the cancer. Researchers will also monitor side effects and how long any benefits last.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- oral azacitidine (CC-486)
- What this could lead to
- If successful, this could offer a new oral treatment option for patients with T-LGLL leukemia that has not responded to standard therapies.
- What could go wrong
- This is a very small early-phase trial (11 participants) testing safety and dosing, so it may not lead to a proven treatment. Side effects of azacitidine are possible, and the cancer may still progress.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T-CELL LARGE GRANULAR LYMPHOCYTE LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
University of Virginia
Charlottesville, Virginia, 22908, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.